PMC:7161517 / 22164-23121 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T132","span":{"begin":57,"end":61},"obj":"Body_part"},{"id":"T133","span":{"begin":198,"end":205},"obj":"Body_part"},{"id":"T134","span":{"begin":419,"end":424},"obj":"Body_part"},{"id":"T135","span":{"begin":583,"end":589},"obj":"Body_part"},{"id":"T136","span":{"begin":654,"end":658},"obj":"Body_part"},{"id":"T137","span":{"begin":791,"end":795},"obj":"Body_part"}],"attributes":[{"id":"A132","pred":"fma_id","subj":"T132","obj":"http://purl.org/sig/ont/fma/fma12520"},{"id":"A133","pred":"fma_id","subj":"T133","obj":"http://purl.org/sig/ont/fma/fma83365"},{"id":"A134","pred":"fma_id","subj":"T134","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A135","pred":"fma_id","subj":"T135","obj":"http://purl.org/sig/ont/fma/fma9637"},{"id":"A136","pred":"fma_id","subj":"T136","obj":"http://purl.org/sig/ont/fma/fma12520"},{"id":"A137","pred":"fma_id","subj":"T137","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Ongoing clinical studies assessing the modulation of RAS axis include: 1) the assessment of the relative activity of ACE and ACE2 in patients with diabetes following treatment with candesartan (Non-Insulin Dependent Diabetes Mellitus [NIDDM] and Angiotensin Converting Enzyme 2 [ACE2]: Diabetic Patients Treated With Antihypertensive Drugs; NCT00192803); and 2) the overexpression of ACE2/Ang 1-7 in cardiac progenitor cells to assess for enhancement in reparative function and the potential to attenuate myocardial ischemia−induced cardiac damage (Cardiovascular Disease Protection Tissue; NCT02348515). It is evident that targeting the ACE2/Ang1-7/Mas axis is going to be interesting in clinical settings because of the observed cardioprotective effects in the in vivo murine and in vitro cell culture models. However, further investigation is required to demonstrate whether these favorable experimental effects could be translated into clinical benefit."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T67","span":{"begin":53,"end":56},"obj":"Body_part"},{"id":"T68","span":{"begin":583,"end":589},"obj":"Body_part"}],"attributes":[{"id":"A67","pred":"uberon_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"},{"id":"A68","pred":"uberon_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/UBERON_0000479"}],"text":"Ongoing clinical studies assessing the modulation of RAS axis include: 1) the assessment of the relative activity of ACE and ACE2 in patients with diabetes following treatment with candesartan (Non-Insulin Dependent Diabetes Mellitus [NIDDM] and Angiotensin Converting Enzyme 2 [ACE2]: Diabetic Patients Treated With Antihypertensive Drugs; NCT00192803); and 2) the overexpression of ACE2/Ang 1-7 in cardiac progenitor cells to assess for enhancement in reparative function and the potential to attenuate myocardial ischemia−induced cardiac damage (Cardiovascular Disease Protection Tissue; NCT02348515). It is evident that targeting the ACE2/Ang1-7/Mas axis is going to be interesting in clinical settings because of the observed cardioprotective effects in the in vivo murine and in vitro cell culture models. However, further investigation is required to demonstrate whether these favorable experimental effects could be translated into clinical benefit."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T92","span":{"begin":147,"end":155},"obj":"Disease"},{"id":"T93","span":{"begin":194,"end":233},"obj":"Disease"},{"id":"T94","span":{"begin":198,"end":233},"obj":"Disease"},{"id":"T95","span":{"begin":235,"end":240},"obj":"Disease"},{"id":"T97","span":{"begin":505,"end":524},"obj":"Disease"},{"id":"T98","span":{"begin":516,"end":524},"obj":"Disease"},{"id":"T99","span":{"begin":549,"end":571},"obj":"Disease"}],"attributes":[{"id":"A92","pred":"mondo_id","subj":"T92","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A93","pred":"mondo_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/MONDO_0005148"},{"id":"A94","pred":"mondo_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/MONDO_0005147"},{"id":"A95","pred":"mondo_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/MONDO_0005148"},{"id":"A96","pred":"mondo_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/MONDO_0007455"},{"id":"A97","pred":"mondo_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/MONDO_0024644"},{"id":"A98","pred":"mondo_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/MONDO_0005053"},{"id":"A99","pred":"mondo_id","subj":"T99","obj":"http://purl.obolibrary.org/obo/MONDO_0004995"}],"text":"Ongoing clinical studies assessing the modulation of RAS axis include: 1) the assessment of the relative activity of ACE and ACE2 in patients with diabetes following treatment with candesartan (Non-Insulin Dependent Diabetes Mellitus [NIDDM] and Angiotensin Converting Enzyme 2 [ACE2]: Diabetic Patients Treated With Antihypertensive Drugs; NCT00192803); and 2) the overexpression of ACE2/Ang 1-7 in cardiac progenitor cells to assess for enhancement in reparative function and the potential to attenuate myocardial ischemia−induced cardiac damage (Cardiovascular Disease Protection Tissue; NCT02348515). It is evident that targeting the ACE2/Ang1-7/Mas axis is going to be interesting in clinical settings because of the observed cardioprotective effects in the in vivo murine and in vitro cell culture models. However, further investigation is required to demonstrate whether these favorable experimental effects could be translated into clinical benefit."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T220","span":{"begin":105,"end":113},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T221","span":{"begin":198,"end":205},"obj":"http://purl.obolibrary.org/obo/PR_000009054"},{"id":"T222","span":{"begin":419,"end":424},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T223","span":{"begin":791,"end":795},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"Ongoing clinical studies assessing the modulation of RAS axis include: 1) the assessment of the relative activity of ACE and ACE2 in patients with diabetes following treatment with candesartan (Non-Insulin Dependent Diabetes Mellitus [NIDDM] and Angiotensin Converting Enzyme 2 [ACE2]: Diabetic Patients Treated With Antihypertensive Drugs; NCT00192803); and 2) the overexpression of ACE2/Ang 1-7 in cardiac progenitor cells to assess for enhancement in reparative function and the potential to attenuate myocardial ischemia−induced cardiac damage (Cardiovascular Disease Protection Tissue; NCT02348515). It is evident that targeting the ACE2/Ang1-7/Mas axis is going to be interesting in clinical settings because of the observed cardioprotective effects in the in vivo murine and in vitro cell culture models. However, further investigation is required to demonstrate whether these favorable experimental effects could be translated into clinical benefit."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T268","span":{"begin":53,"end":56},"obj":"Chemical"},{"id":"T269","span":{"begin":181,"end":192},"obj":"Chemical"},{"id":"T270","span":{"begin":198,"end":205},"obj":"Chemical"},{"id":"T271","span":{"begin":246,"end":257},"obj":"Chemical"}],"attributes":[{"id":"A268","pred":"chebi_id","subj":"T268","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"},{"id":"A269","pred":"chebi_id","subj":"T269","obj":"http://purl.obolibrary.org/obo/CHEBI_3347"},{"id":"A270","pred":"chebi_id","subj":"T270","obj":"http://purl.obolibrary.org/obo/CHEBI_5931"},{"id":"A271","pred":"chebi_id","subj":"T271","obj":"http://purl.obolibrary.org/obo/CHEBI_2719"}],"text":"Ongoing clinical studies assessing the modulation of RAS axis include: 1) the assessment of the relative activity of ACE and ACE2 in patients with diabetes following treatment with candesartan (Non-Insulin Dependent Diabetes Mellitus [NIDDM] and Angiotensin Converting Enzyme 2 [ACE2]: Diabetic Patients Treated With Antihypertensive Drugs; NCT00192803); and 2) the overexpression of ACE2/Ang 1-7 in cardiac progenitor cells to assess for enhancement in reparative function and the potential to attenuate myocardial ischemia−induced cardiac damage (Cardiovascular Disease Protection Tissue; NCT02348515). It is evident that targeting the ACE2/Ang1-7/Mas axis is going to be interesting in clinical settings because of the observed cardioprotective effects in the in vivo murine and in vitro cell culture models. However, further investigation is required to demonstrate whether these favorable experimental effects could be translated into clinical benefit."}

{"project":"LitCovid-sentences","denotations":[{"id":"T139","span":{"begin":0,"end":70},"obj":"Sentence"},{"id":"T140","span":{"begin":71,"end":285},"obj":"Sentence"},{"id":"T141","span":{"begin":286,"end":604},"obj":"Sentence"},{"id":"T142","span":{"begin":605,"end":811},"obj":"Sentence"},{"id":"T143","span":{"begin":812,"end":957},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Ongoing clinical studies assessing the modulation of RAS axis include: 1) the assessment of the relative activity of ACE and ACE2 in patients with diabetes following treatment with candesartan (Non-Insulin Dependent Diabetes Mellitus [NIDDM] and Angiotensin Converting Enzyme 2 [ACE2]: Diabetic Patients Treated With Antihypertensive Drugs; NCT00192803); and 2) the overexpression of ACE2/Ang 1-7 in cardiac progenitor cells to assess for enhancement in reparative function and the potential to attenuate myocardial ischemia−induced cardiac damage (Cardiovascular Disease Protection Tissue; NCT02348515). It is evident that targeting the ACE2/Ang1-7/Mas axis is going to be interesting in clinical settings because of the observed cardioprotective effects in the in vivo murine and in vitro cell culture models. However, further investigation is required to demonstrate whether these favorable experimental effects could be translated into clinical benefit."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T31","span":{"begin":194,"end":233},"obj":"Phenotype"},{"id":"T32","span":{"begin":235,"end":240},"obj":"Phenotype"},{"id":"T33","span":{"begin":549,"end":571},"obj":"Phenotype"}],"attributes":[{"id":"A31","pred":"hp_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/HP_0005978"},{"id":"A32","pred":"hp_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/HP_0005978"},{"id":"A33","pred":"hp_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/HP_0001626"}],"text":"Ongoing clinical studies assessing the modulation of RAS axis include: 1) the assessment of the relative activity of ACE and ACE2 in patients with diabetes following treatment with candesartan (Non-Insulin Dependent Diabetes Mellitus [NIDDM] and Angiotensin Converting Enzyme 2 [ACE2]: Diabetic Patients Treated With Antihypertensive Drugs; NCT00192803); and 2) the overexpression of ACE2/Ang 1-7 in cardiac progenitor cells to assess for enhancement in reparative function and the potential to attenuate myocardial ischemia−induced cardiac damage (Cardiovascular Disease Protection Tissue; NCT02348515). It is evident that targeting the ACE2/Ang1-7/Mas axis is going to be interesting in clinical settings because of the observed cardioprotective effects in the in vivo murine and in vitro cell culture models. However, further investigation is required to demonstrate whether these favorable experimental effects could be translated into clinical benefit."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T766","span":{"begin":39,"end":49},"obj":"GO:0065007"},{"id":"T767","span":{"begin":125,"end":129},"obj":"G_3;PG_10;PR:000003622"},{"id":"T768","span":{"begin":198,"end":205},"obj":"PR:000009054"},{"id":"T769","span":{"begin":246,"end":277},"obj":"PG_10;PR:000003622"},{"id":"T770","span":{"begin":279,"end":283},"obj":"G_3;PG_10;PR:000003622"},{"id":"T771","span":{"begin":334,"end":339},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T772","span":{"begin":366,"end":380},"obj":"GO:0010467"},{"id":"T773","span":{"begin":384,"end":388},"obj":"G_3;PG_10;PR:000003622"},{"id":"T774","span":{"begin":389,"end":396},"obj":"PR:000036013"},{"id":"T775","span":{"begin":400,"end":407},"obj":"UBERON:0000948"},{"id":"T776","span":{"begin":505,"end":515},"obj":"UBERON:0002349"},{"id":"T777","span":{"begin":533,"end":540},"obj":"UBERON:0000948"},{"id":"T778","span":{"begin":549,"end":563},"obj":"UBERON:0004535"},{"id":"T779","span":{"begin":583,"end":589},"obj":"UBERON:0000479"},{"id":"T780","span":{"begin":638,"end":642},"obj":"G_3;PG_10;PR:000003622"},{"id":"T781","span":{"begin":643,"end":647},"obj":"PR:000036013"},{"id":"T782","span":{"begin":771,"end":777},"obj":"NCBITaxon:39107"},{"id":"T783","span":{"begin":782,"end":795},"obj":"CL:0001034"},{"id":"T83220","span":{"begin":71,"end":76},"obj":"NCBITaxon:39107"},{"id":"T99627","span":{"begin":81,"end":94},"obj":"CL:0001034"},{"id":"T57790","span":{"begin":257,"end":261},"obj":"G_3;PG_10;PR:000003622"},{"id":"T74175","span":{"begin":263,"end":271},"obj":"SP_7"},{"id":"T41191","span":{"begin":277,"end":291},"obj":"UBERON:0004535"},{"id":"T25778","span":{"begin":326,"end":334},"obj":"SP_7"},{"id":"T84221","span":{"begin":354,"end":361},"obj":"UBERON:0000948"},{"id":"T89571","span":{"begin":432,"end":440},"obj":"SP_7"},{"id":"T85711","span":{"begin":495,"end":514},"obj":"PR:000005897"},{"id":"T57094","span":{"begin":576,"end":586},"obj":"UBERON:0002349"},{"id":"T15258","span":{"begin":663,"end":670},"obj":"UBERON:0000948"},{"id":"T1531","span":{"begin":803,"end":813},"obj":"UBERON:0002349"},{"id":"T97341","span":{"begin":839,"end":846},"obj":"UBERON:0000948"},{"id":"T2733","span":{"begin":885,"end":893},"obj":"UBERON:0001621"},{"id":"T89171","span":{"begin":947,"end":955},"obj":"SP_7"}],"text":"Ongoing clinical studies assessing the modulation of RAS axis include: 1) the assessment of the relative activity of ACE and ACE2 in patients with diabetes following treatment with candesartan (Non-Insulin Dependent Diabetes Mellitus [NIDDM] and Angiotensin Converting Enzyme 2 [ACE2]: Diabetic Patients Treated With Antihypertensive Drugs; NCT00192803); and 2) the overexpression of ACE2/Ang 1-7 in cardiac progenitor cells to assess for enhancement in reparative function and the potential to attenuate myocardial ischemia−induced cardiac damage (Cardiovascular Disease Protection Tissue; NCT02348515). It is evident that targeting the ACE2/Ang1-7/Mas axis is going to be interesting in clinical settings because of the observed cardioprotective effects in the in vivo murine and in vitro cell culture models. However, further investigation is required to demonstrate whether these favorable experimental effects could be translated into clinical benefit."}

{"project":"LitCovid-PubTator","denotations":[{"id":"974","span":{"begin":117,"end":120},"obj":"Gene"},{"id":"975","span":{"begin":125,"end":129},"obj":"Gene"},{"id":"976","span":{"begin":246,"end":277},"obj":"Gene"},{"id":"977","span":{"begin":279,"end":283},"obj":"Gene"},{"id":"978","span":{"begin":384,"end":388},"obj":"Gene"},{"id":"979","span":{"begin":389,"end":396},"obj":"Gene"},{"id":"980","span":{"begin":638,"end":642},"obj":"Gene"},{"id":"981","span":{"begin":643,"end":649},"obj":"Gene"},{"id":"982","span":{"begin":133,"end":141},"obj":"Species"},{"id":"983","span":{"begin":295,"end":303},"obj":"Species"},{"id":"984","span":{"begin":771,"end":777},"obj":"Species"},{"id":"985","span":{"begin":147,"end":155},"obj":"Disease"},{"id":"986","span":{"begin":194,"end":233},"obj":"Disease"},{"id":"987","span":{"begin":235,"end":240},"obj":"Disease"},{"id":"988","span":{"begin":286,"end":294},"obj":"Disease"},{"id":"989","span":{"begin":505,"end":524},"obj":"Disease"},{"id":"990","span":{"begin":533,"end":547},"obj":"Disease"},{"id":"991","span":{"begin":549,"end":571},"obj":"Disease"}],"attributes":[{"id":"A974","pred":"tao:has_database_id","subj":"974","obj":"Gene:1636"},{"id":"A975","pred":"tao:has_database_id","subj":"975","obj":"Gene:59272"},{"id":"A976","pred":"tao:has_database_id","subj":"976","obj":"Gene:59272"},{"id":"A977","pred":"tao:has_database_id","subj":"977","obj":"Gene:59272"},{"id":"A978","pred":"tao:has_database_id","subj":"978","obj":"Gene:59272"},{"id":"A979","pred":"tao:has_database_id","subj":"979","obj":"Gene:284"},{"id":"A980","pred":"tao:has_database_id","subj":"980","obj":"Gene:70008"},{"id":"A981","pred":"tao:has_database_id","subj":"981","obj":"Gene:11727"},{"id":"A982","pred":"tao:has_database_id","subj":"982","obj":"Tax:9606"},{"id":"A983","pred":"tao:has_database_id","subj":"983","obj":"Tax:9606"},{"id":"A984","pred":"tao:has_database_id","subj":"984","obj":"Tax:10090"},{"id":"A985","pred":"tao:has_database_id","subj":"985","obj":"MESH:D003920"},{"id":"A986","pred":"tao:has_database_id","subj":"986","obj":"MESH:D003924"},{"id":"A987","pred":"tao:has_database_id","subj":"987","obj":"MESH:D003924"},{"id":"A988","pred":"tao:has_database_id","subj":"988","obj":"MESH:D003920"},{"id":"A989","pred":"tao:has_database_id","subj":"989","obj":"MESH:D003324"},{"id":"A990","pred":"tao:has_database_id","subj":"990","obj":"MESH:D006331"},{"id":"A991","pred":"tao:has_database_id","subj":"991","obj":"MESH:D002318"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Ongoing clinical studies assessing the modulation of RAS axis include: 1) the assessment of the relative activity of ACE and ACE2 in patients with diabetes following treatment with candesartan (Non-Insulin Dependent Diabetes Mellitus [NIDDM] and Angiotensin Converting Enzyme 2 [ACE2]: Diabetic Patients Treated With Antihypertensive Drugs; NCT00192803); and 2) the overexpression of ACE2/Ang 1-7 in cardiac progenitor cells to assess for enhancement in reparative function and the potential to attenuate myocardial ischemia−induced cardiac damage (Cardiovascular Disease Protection Tissue; NCT02348515). It is evident that targeting the ACE2/Ang1-7/Mas axis is going to be interesting in clinical settings because of the observed cardioprotective effects in the in vivo murine and in vitro cell culture models. However, further investigation is required to demonstrate whether these favorable experimental effects could be translated into clinical benefit."}